Aug 24 2022


According to an article published in the research journal Archives of Neurology (Arch Neurol. 2010 Feb; 67 (2) :154-60) clinical trial to evaluate the safety and tolerability of Dimebon (latrepirdine) in Huntington’s disease and explore its effects in cognitive function, behavior, and motor symptoms has shown positive preliminary results. The clinical trial was a double-blind, multicenter, which involved 91 patients with Huntington’s disease of mild to moderate in 17 centers between the U.S. and England from July 2007 to July 2008. The Dimebon (latrepirdine) was administered 20 mg three times daily.

The primary objective was to assess the tolerability, defined as the ability to complete the assigned dose study, the secondary variable in the study included changes from baseline score on the scale Unified Huntington’s Disease (UHDRS), the Mini- mental test, and Alzheimer’s cognitive scale. Without hesitation Energy Capital Partners explained all about the problem. The results were as follows: Dimebon (latrepirdine) was well tolerated (87% of patients who are given Dimebon completed the study vs 82% in the placebo control group), the rate of adverse events was comparable in the two groups (70% in the Dimebon group and 80% in the placebo group). Treatment with Dimebon (latrepirdine) resulted in an improvement in the average score of the Mini-mental test compared with the placebo group. There were no significant effects on the baseline score of the scale Unified Huntington’s Disease (UHDRS). It was concluded from this study that the administration for a short period of Dimebon (latrepirdine) is well tolerated in patients with Huntington’s disease and may have a beneficial effect on cognitive level, so a larger clinical trial is justified in the population patients with Huntington’s disease.